Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 299, Issue 3, 2010, Pages

  Bello, Nicholas T ^a   Kemm, Matthew H ^a   Ofeldt, Erica M ^a   Moran, Timothy H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Exenatide; Gut peptides; Islet amyloid polypeptide; Obesity

Indexed keywords

AMYLIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; SALCATONIN; CALCITONIN; PEPTIDE; VENOM;

ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG POTENTIATION; EATING; FEEDBACK SYSTEM; FOOD INTAKE; MALE; MEAL; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REPEATED DRUG DOSE; RHESUS MONKEY; ANIMAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; FEEDING BEHAVIOR;

ANIMALS; CALCITONIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EATING; FEEDING BEHAVIOR; MACACA MULATTA; MALE; PEPTIDES; VENOMS;

EID: 77956699440     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00275.2010     Document Type: Article

References (59)

1. Aaboe K, Krarup T, Madsbad S, Holst JJ. GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes Metab 10: 994-1003, 2008.
2. Ai G, Chen Z, Shan C, Che J, Hou Y, Cheng Y. Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. Int J Pharm 353: 56-64, 2008.
3. Bello NT, Kemm MH, Moran TH. Salmon calcitonin reduces food intake through changes in meal sizes in male rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 295: R76-R81, 2008.
4. Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145: 2653-2659, 2004.
5. Chan JL, Roth JD, Weyer C. It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development. J Investig Med 57: 777-783, 2009.
6. Chen HC, Roth JD, Schroeder BE, Weyer C. Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy. Curr Diabetes Rev 4: 79-91, 2008.
7. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N, Holland J, Hembree J, Abplanalp W, Grant E, Ruehl J, Wilson H, Kirchner H, Lockie SH, Hofmann S, Woods SC, Nogueiras R, Pfluger PT, Perez-Tilve D, DiMarchi R, Tschop MH. A new glucagon and GLP-1 coagonist eliminates obesity in rodents. Nat Chem Biol 5: 749-757, 2009.
8. Del Prete E, Schade B, Riediger T, Lutz TA, Scharrer E. Effects of amylin and salmon calcitonin on feeding and drinking behavior in pygmy goats. Physiol Behav 75: 593-599, 2002. (Pubitemid 34327967)
9. Emond M, Schwartz GJ, Ladenheim EE, Moran TH. Central leptin modulates behavioral and neural responsivity to CCK. Am J Physiol Regul Integr Comp Physiol 276: R1545-R1549, 1999.
10. Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 34 Suppl 2: S65-S72, 2008.
11. Gennings C, Carter WH Jr, Campbell ED, Staniswalis JG, Martin TJ, Martin BR, and White KL, Jr. Isobolographic characterization of drug interactions incorporating biological variability. J Pharmacol Exp Ther 252: 208-217, 1990. (Pubitemid 20067715)
12. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7: 2294-2300, 1995.
13. Hayes MR, De Jonghe BC, Kanoski SE. Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol Behav 100: 503-510, 2010.
14. Hayes MR, Skibicka KP, Grill HJ. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 149: 4059-4068, 2008.
15. Hilton JM, Dowton M, Houssami S, Sexton PM. Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors. J Endocrinol 166: 213-226, 2000. (Pubitemid 30435891)
16. Johnson KH, O'Brien TD, Westermark P. Newly identified pancreatic protein islet amyloid polypeptide. What is its relationship to diabetes? Diabetes 40: 310-314, 1991.
17. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18: 7-14, 2002. (Pubitemid 34252619)
18. Kinzig KP, D'Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 22: 10470-10476, 2002.
19. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet 339: 1179-1180, 1992.
20. Lutz TA. Amylinergic control of food intake. Physiol Behav 89: 465-471, 2006.
21. Lutz TA, Senn M, Althaus J, Del Prete E, Ehrensperger F, Scharrer E. Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides 19: 309-317, 1998. (Pubitemid 28097930)
22. Lutz TA, Tschudy S, Rushing PA, Scharrer E. Amylin receptors mediate the anorectic action of salmon calcitonin (sCT). Peptides 21: 233-238, 2000. (Pubitemid 30182486)
23. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 30: 1332-1340, 2006. (Pubitemid 44306514)
24. Mack CM, Soares CJ, Wilson JK, Athanacio JR, Turek VF, Trevaskis JL, Roth JD, Smith PA, Gedulin B, Jodka CM, Roland BL, Adams SH, Lwin A, Herich J, Laugero KD, Vu C, Pittner R, Paterniti JR Jr, Hanley M, Ghosh S, Parkes DG. Davalintide (AC2307), a novel amylinmimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int J Obes (Lond) 34: 385-395, 2010.
25. Matson CA, Reid DF, Cannon TA, Ritter RC. Cholecystokinin and leptin act synergistically to reduce body weight. Am J Physiol Regul Integr Comp Physiol 278: R882-R890, 2000.
26. Matson CA, Ritter RC. Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight. Am J Physiol Regul Integr Comp Physiol 276: R1038-R1045, 1999.
27. Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 265: 8001-8008, 1990. (Pubitemid 20158973)
28. Mollet A, Lutz TA, Meier S, Riediger T, Rushing PA, Scharrer E. Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am J Physiol Regul Integr Comp Physiol 281: R1442-R1448, 2001.
29. Moran TH. Cholecystokinin and satiety: current perspectives. Nutrition 16: 858-865, 2000.
30. Moran TH. Gut peptides in the control of food intake. Int J Obes (Lond) 33 Suppl 1: S7-S10, 2009.
31. Morley JE, Flood JF, Horowitz M, Morley PM, Walter MJ. Modulation of food intake by peripherally administered amylin. Am J Physiol Regul Integr Comp Physiol 267: R178-R184, 1994. (Pubitemid 2123484)
32. Nagell CF, Wettergren A, Orskov C, Holst JJ. Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand J Gastroenterol 41: 667-672, 2006. (Pubitemid 43995007)
33. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, Young A. Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug Dev Res 53: 260-267, 2001. (Pubitemid 33029654)
34. Perlow MJ, Freed WJ, Carman JS, Wyatt RJ. Calcitonin reduces feeding in man, monkey and rat. Pharmacol Biochem Behav 12: 609-612, 1980.
35. Pohl M, Wank SA. Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues. J Biol Chem 273: 9778-9784, 1998. (Pubitemid 28183071)
36. Potes CS, Lutz TA. Brainstem mechanisms of amylin-induced anorexia. Physiol Behav 100: 511-518, 2010.
37. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. International Union of Pharmacology. XXXII The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 54: 233-246, 2002. (Pubitemid 34575714)
38. Ranganath LR. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. J Clin Pathol 61: 401-409, 2008.
39. Raufman JP, Jensen RT, Sutliff VE, Pisano JJ, Gardner JD. Actions of Gila monster venom on dispersed acini from guinea pig pancreas. Am J Physiol Gastrointest Liver Physiol 242: G470-G474, 1982.
40. Riediger T, Schmid HA, Lutz TA, Simon E. Amylin and glucose co-activate area postrema neurons of the rat. Neurosci Lett 328: 121-124, 2002. (Pubitemid 34804726)
41. Rong H, Deftos LJ, Ji H, Bucht E. Two-site immunofluorometric assay of intact salmon calcitonin with improved sensitivity. Clin Chem 43: 71-75, 1997. (Pubitemid 27024393)
42. Roth JD, Coffey T, Jodka CM, Maier H, Athanacio JR, Mack CM, Weyer C, Parkes DG. Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology 148: 6054-6061, 2007. (Pubitemid 350146144)
43. Roth JD, Hughes H, Kendall E, Baron AD, Anderson CM. Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 147: 5855-5864, 2006. (Pubitemid 44833502)
44. Roth JD, Maier H, Chen S, Roland BL. Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol 66: 306-310, 2009.
45. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 105: 7257-7262, 2008. (Pubitemid 351754465)
46. Roth JD, Trevaskis JL, Turek VF, Parkes DG. "Weighing in" on synergy: Preclinical research on neurohormonal anti-obesity combinations. Brain Res. In press.
47. Rowland NE, Crews EC, Gentry RM. Comparison of Fos induced in rat brain by GLP-1 and amylin. Regul Pept 71: 171-174, 1997.
48. Schumacher PM, Dossche J, Mortier EP, Luginbuehl M, Bouillon TW, Struys MM. Response surface modeling of the interaction between propofol and sevoflurane. Anesthesiology 111: 790-804, 2009.
49. Scott KA, Moran TH. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 293: R983-R987, 2007.
50. Smith SR, Blundell JE, Burns C, Ellero C, Schroeder BE, Kesty NC, Chen KS, Halseth AE, Lush CW, Weyer C. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab 293: E620-E627, 2007.
51. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, Sheikh SP. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol Regul Integr Comp Physiol 271: R848-R856, 1996.
52. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 25 Suppl 5: S42-S47, 2001.
53. Trevaskis JL, Coffey T, Cole R, Lei C, Wittmer C, Walsh B, Weyer C, Koda J, Baron AD, Parkes DG, Roth JD. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 149: 5679-5687, 2008.
54. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86: 4382-4389, 2001. (Pubitemid 32848563)
55. Wang F, Westermark G, Gasslander T, Permert J. Effect of islet amyloid polypeptide on somatostatin inhibition of insulin secretion from isolated rat pancreatic islets. Regul Pept 72: 61-67, 1997. (Pubitemid 27492063)
56. Wielinga PY, Alder B, Lutz TA. The acute effect of amylin and salmon calcitonin on energy expenditure. Physiol Behav 91: 212-217, 2007. (Pubitemid 46770799)
57. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150: 1680-1687, 2009.
58. Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 55: 3387-3393, 2006.
59. Young AA. Inhibition of gastric emptying. Adv Pharmacol 52: 99-121, 2005.